Compare Danaher Corporation (DHR) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Yum China Holdings Inc — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while Yum China Holdings Inc trades at $47.71 (market cap $16.28B). The key difference: Danaher Corporation is far larger — about 9× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.44%). Which is the better fit depends on your goals.
| DHR | YUMC | |
|---|---|---|
Market Cap | $145.83B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $57.95 |
52-Week Low | $161.91 | $40.18 |
Enterprise Value | $168.04B | $17.19B |
Dividend Yield | 0.77% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
YUMC trades at $47.92, down 0.56% on the day, with a bullish technical signal supported by moving averages. The company demonstrates consistent fundamental strength with Q2 2026 earnings beating estimates, revenue growth of 13% year-over-year, and a net income margin of 7.84%. Recent completion of the Pizza Hut China acquisition for $1.2 billion positions the company for strategic growth and cost synergies.
The outlook remains positive with strong analyst support (73.68% buy ratings) and a 26.21% upside potential. Key risks include Chinese macroeconomic headwinds and integration challenges from the Pizza Hut acquisition. Earnings momentum and valuation metrics suggest continued growth potential for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
